The Institute for Safe Medication Practices has released a report warning that severe side effects, including liver failure, have been associated with the new direct-acting antiviral (DAA) drugs that now are able to cure hepatitis C virus in more than 98% of most patients.
Using data from the FDA Adverse Event Reporting System, ISMP analysts found that among the approximately 250,000 patients treated with one of the nine currently approved DAAs in the United States during the year ending June